3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Conditions
Colorectal Neoplasms
42
Neoplasms
14
Carcinoma, Hepatocellular
9
Gastrointestinal Stromal Tumors
7
Liver Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Glioblastoma
2
Esophageal Squamous Cell Carcinoma
2
Astrocytoma
2
Advanced Cancer
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Malignant Tumors
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Renal Insufficiency
1
Rectal Neoplasms
1
Physician Education
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Melanoma
1
Interventions
Standard of Care
2
COVID-19 Vaccines
2
regorafenib
1
proxalutamide
1
palbociclib
1
cilgavimab and tixagevimab drug combination
1
bemcentinib
1
acalabrutinib
1
Sorafenib
1
Sodium Chloride
1
Rabeprazole
1
NVX-CoV2373 adjuvated lipid nanoparticle
1
Janus Kinase Inhibitors
1
Interleukin-7
1
IBIO123
1
Gelsolin
1
COH04S1 COVID-19 vaccine
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
2019-nCoV Vaccine mRNA-1273
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
COVID-19
×
regorafenib
×
Clear all
NCT05594147
2023-11-07
ROCURS
Bayer
Completed
4,103 enrolled